Biological imaging in radiation oncology

A decade in prostate cancer: from NMR to metabolomics

Over the past 30 years, continuous progress in the application of nuclear magnetic resonance (NMR) spectroscopy and magnetic resonance spectroscopic imaging (MRSI) to the detection, diagnosis and characterization of human prostate cancer has turned what began as scientific curiosity into a useful clinical option. In vivo MRSI technology has been integrated into the daily care of prostate cancer patients, and innovations in ex vivo methods have helped to establish NMR-based prostate cancer metabolomics. Metabolomic and multimodality imaging could be the future of the prostate cancer clinic--particularly given the rationale that more accurate interrogation of a disease as complex as human prostate cancer is most likely to be achieved through paradigms involving multiple, instead of single and isolated, parameters. The research and clinical results achieved through in vivo MRSI and ex vivo NMR investigations during the first 11 years of the 21st century illustrate areas where these technologies can be best translated into clinical practice.

Molecular PET/CT imaging-guided radiation therapy treatment planning

The role of positron emission tomography (PET) during the past decade has evolved rapidly from that of a pure research tool to a methodology of enormous clinical potential. (18)F-fluorodeoxyglucose (FDG)-PET is currently the most widely used probe in the diagnosis, staging, assessment of tumor response to treatment, and radiation therapy planning because metabolic changes generally precede the more conventionally measured parameter of change in tumor size. Data accumulated rapidly during the last decade, thus validating the efficacy of FDG imaging and many other tracers in a wide variety of malignant tumors with sensitivities and specificities often in the high 90 percentile range. As a result, PET/computed tomography (CT) had a significant impact on the management of patients because it obviated the need for further evaluation, guided further diagnostic procedures, and assisted in planning therapy for a considerable number of patients. On the other hand, the progress in radiation therapy technology has been enormous during the last two decades, now offering the possibility to plan highly conformal radiation dose distributions through the use of sophisticated beam targeting techniques such as intensity-modulated radiation therapy (IMRT) using tomotherapy, volumetric modulated arc therapy, and many other promising technologies for sculpted three-dimensional (3D) dose distribution. The foundation of molecular imaging-guided radiation therapy lies in the use of advanced imaging technology for improved definition of tumor target volumes, thus relating the absorbed dose information to image-based patient representations. This review documents technological advancements in the field concentrating on the conceptual role of molecular PET/CT imaging in radiation therapy treatment planning and related image processing issues with special emphasis on segmentation of medical images for the purpose of defining target volumes. There is still much more work to be done and many of the techniques reviewed are themselves not yet widely implemented in clinical settings.

Functional and metabolic magnetic resonance imaging and positron emission tomography for tumor volume definition in high-grade gliomas

Although the addition of concurrent and adjuvant temozolomide (TMZ) to standard-dose radiation (60 Gy) improves survival, the pattern of failure continues to be local. Conventional contrast enhanced T1-weighted and T2-weighted magnetic resonance imaging (MRI) used for radiation planning reflect anatomic rather than molecular or functional, properties of the tumor. Functional and metabolic MRI and positron emission tomography are able to detect metabolic and functional abnormalities beyond the tumor volume seen on conventional MRI, assess early response to treatment, and delineate the regions of high risks for failure in high-grade gliomas. This article focuses on the potential of these functional and metabolic imaging techniques to refine our clinical target volumes.

Application of the Inverse Monte Carlo Treatment Planning System IKO for an Inhomogeneous Dose Prescription in the Sense of Dose Painting* *This work was presented at the ICMP 2005 and awarded by the Siemens Prize

Biological imaging (PET SPECTJfMRI, MRS, etc.) is able to provide tri-dimensional biological information, i.e. proliferation, cell density, hypoxia or choline/citrate ratio. The implementation of this information in a treatment plan can be utilised to escalate the dose in target subvolumes. For this purpose, a treatment planning system has to be able to realise an inhomogeneous dose prescription with sufficient spatial resolution. The present study investigated to which extent the inverse Monte Carlo treatment planning system IKO (inverse kernel optimization), developed at our department, can modulate an inhomogeneous dose prescription. As a qualifier to describe this ability, we defined in analogy to imaging a modulation transfer function for treatment planning systems. In addition two clinical cases, a prostate case and a head-and-neck case, were set up with different dose prescriptions in different subtargets. The modulation transfer function revealed that IKO is able to modulate structures larger than 1.3 cm with sharp dose gradients. Also, IKO is able to modulate several subtargets inside a prostate with different escalated doses. The dose-volume histograms of the head-and-neck case showed a good dose coverage of the target volumes, as well as a good protection of the organs at risk according to the dose constraints. As a result, IKO is able to realise a heterogeneous dose prescription in the sense of "dose painting".